In a 65-year-old woman with metastatic breast cancer who recently underwent femur fixation, does letrozole affect serum creatine kinase (CK) and CK‑MB levels, and can it cause thrombocytopenia?

Letrozole Does Not Directly Cause Elevated CK/CK-MB or Thrombocytopenia in Breast Cancer Patients

Letrozole itself is not associated with causing elevated creatine kinase (CK) or CK-MB levels, nor does it directly cause thrombocytopenia in breast cancer patients. The FDA-approved prescribing information for letrozole does not list these as recognized adverse effects 1.

Effect on CK and CK-MB Levels

Letrozole's mechanism of action involves selective aromatase inhibition, which suppresses estrogen biosynthesis without affecting adrenal steroidogenesis, mineralocorticoid or glucocorticoid synthesis, or thyroid function 1. The drug does not have known direct effects on muscle tissue or cardiac enzymes that would elevate CK or CK-MB.

However, in your specific clinical scenario post-femur fixation, any CK/CK-MB elevation is far more likely attributable to:

• Surgical trauma from the femur fixation procedure - orthopedic surgery causes significant muscle and tissue injury with expected CK elevation
• Bone metastases themselves - metastatic breast cancer to bone can cause paradoxical CK-MB elevations through non-cardiac CK isoenzymes, particularly CK-BB (brain-type) and mitochondrial CK 2
• Immobilization and muscle breakdown following orthopedic surgery

Recent research demonstrates that cancer patients, particularly those with colorectal and lung cancers in advanced stages, frequently show CK-MB > total CK abnormalities driven by aberrant increases in CK-BB and mitochondrial CK rather than cardiac muscle damage 2. This phenomenon appears related to platelet-derived CKB and may correlate with metastatic potential.

Thrombocytopenia Risk

Letrozole monotherapy does not cause thrombocytopenia. The FDA label does not list hematologic toxicity as an adverse effect of letrozole alone 1.

Critical distinction: Thrombocytopenia in breast cancer patients on letrozole occurs when letrozole is combined with CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), not from letrozole itself:

• Hematologic toxicities are the most common adverse events with CDK4/6 inhibitors, particularly palbociclib and ribociclib 3, 4
• Neutropenia is most frequent; thrombocytopenia is less common but documented 3, 4
• One case report describes successful treatment with palbociclib plus letrozole in a patient with pre-existing idiopathic thrombocytopenia, though Grade 2 thrombocytopenia did occur during combination therapy 3, 4

In your patient's context, consider alternative causes of thrombocytopenia:

• Bone marrow metastases - breast cancer with bone marrow involvement can present with severe thrombocytopenia and anemia 5
• Perioperative factors - blood loss, hemodilution, or consumptive coagulopathy related to surgery
• Medications - review all concurrent medications for drug-induced thrombocytopenia
• Disseminated intravascular coagulation (DIC) - can occur with advanced metastatic disease 5

Clinical Recommendations

For CK/CK-MB monitoring post-femur fixation:

• Expect elevated CK from surgical trauma; trend values over days to weeks
• If CK-MB appears disproportionately elevated relative to total CK, consider CK isoenzyme electrophoresis to identify non-cardiac sources (CK-BB, mitochondrial CK) related to metastatic disease 2
• Do not attribute these elevations to letrozole

For thrombocytopenia evaluation:

• Obtain complete blood count with differential
• Assess peripheral smear for schistocytes (DIC) or abnormal cells (marrow involvement)
• Check coagulation studies (PT, PTT, fibrinogen, D-dimer) if DIC suspected
• Consider bone marrow biopsy if cytopenias are unexplained and severe, as bone marrow metastases may require modified treatment approach 5
• Do not discontinue letrozole for isolated thrombocytopenia unless other causes are excluded and temporal relationship is compelling

Letrozole can be safely continued in this clinical scenario, as it is appropriate endocrine therapy for hormone receptor-positive metastatic breast cancer 6, 7. The observed laboratory abnormalities warrant investigation for alternative etiologies related to metastatic disease burden, surgical complications, or bone marrow involvement rather than drug toxicity.